NervGen Restates Q2 Results to CAD 10.8 Million Net Income From Net Loss
Bitget2026/10/16 20:32- NervGen Pharma restated financial statements to correct material stock-option and warrant-derivative valuation errors, as well as misclassified share issuance costs.
- Net income for the six months ended June 30, 2026, was corrected to CAD 8.88 million from a CAD 30.89 million loss.
- Warrant derivative liabilities at June 30, 2026, fell to CAD 39.06 million from CAD 68.63 million.
- Shareholders' equity increased to CAD 46.84 million from CAD 17.28 million.
- The errors affected periods beginning in fiscal 2020 through June 30, 2026; corrections did not affect cash flows or cash runway.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic spends $3.4 billion to purchase gas-fired power equipment to supply electricity for data centers
In September, Anthropic directly acquired Caterpillar equipment orders worth 3.4 billion USD, securing 1.7 GW of gas generator units, marking the largest single purchase of power generation equipment in AI history. This move bypassed utility middlemen, capturing scarce capacity at prices set years ago with near-term delivery. It is part of Anthropic's plan to invest over 895 billion USD in computing infrastructure by 2045.

Why Nintendo Stock Is One to Watch Ahead of the Holiday Season

A wallet address sold 1.44 million TRX via SunSwap in exchange for 460,000 USDT.

Data: Whales have cumulatively withdrawn approximately 13.4 million USDT from a certain exchange.